President Trump’s State of the Union address highlighted drug pricing initiatives and other health care proposals, while recent vaccine policy changes sparked legal action and professional concerns about scientific integrity.
Trump’s Drug Pricing Claims
During his first State of the Union address of his second term, Trump claimed he had brought prescription drug costs “from the highest in the world to the lowest,” citing his most-favored nation policy. He urged congressional Republicans to codify the policy into law to prevent his successor from raising drug prices. Trump also touted TrumpRx and other drug pricing policies as a “big achievement.” However, more than half of Americans say health care has become more unaffordable for them and their families.
Health Care Policy Proposals
Trump stated he wants to shift more government funding from premium tax credits to health accounts resembling health savings accounts, promised to crack down on fraud in government programs, and said states should not be allowed to make decisions on gender-affirming care without parental consent. The speech notably omitted discussion of several issues consuming the administration’s HHS department, including vaccine mandate changes and major cuts to health and science funding.
Vaccine Policy Litigation and Concerns
Fifteen states sued HHS over the administration’s changes to federal vaccine recommendations. The American College of Obstetrics and Gynecologists withdrew as a liaison organization to the CDC’s Advisory Committee for Immunization Practices (ACIP), citing concerns about changes “that undermine the committee’s scientific integrity and evidence-based approach to vaccine policy.” A February CDC meeting of the advisory committee was cancelled, with the next gathering scheduled for March 18-19, though a judge could intervene.
Drug Pricing and Cardiovascular Health
Novo Nordisk announced a price reduction for its GLP-1 drugs Ozempic, Rybelus, and Wegovy to $675 per month. The reduction will primarily benefit insured patients who pay coinsurance or those in high-deductible plans. A projection published in Circulation forecasts that 6 in 10 women will develop at least one type of cardiovascular disease over the next 25 years, with nearly a third of girls ages 2 to 19 projected to be in the obese weight category by 2050.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.statnews.com/2026/02/25/health-news-drug-pricing-trump-plan-hhs-concerns/